Ohad Ziv
Cardiovascular Disease · Cleveland, OHNPI 1336369230
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $700 of the $749 with a category attached, or 93.5%. Biosense Webster, Inc. accounts for 93.5% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for cardiovascular disease clinicians in OH, where the typical reported total is $1,347.
Across 2 payments — averaging $374.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biosense Webster, Inc.$700
- Abbott$49
Across 14 payments — averaging $8927.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biosense Webster, Inc.$113K
- Boston Scientific$12K
What the payments were for
- Consulting fees$70094%
- Food & beverage$496%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biosense Webster, Inc. | 1 | $700 |
| Abbott | 1 | $49 |
How this compares
$749 in reported general payments places this provider in the 35th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 123 | $172,171 |
| EliquisApixaban | 124 | $143,269 |
| Dofetilide | 106 | $20,620 |
| FarxigaDapagliflozin Propanediol | 17 | $14,161 |
| Metoprolol Succinate | 224 | $3,938 |
| Flecainide Acetate | 60 | $1,926 |
| Mexiletine Hcl | 24 | $1,551 |
| SotalolSotalol Hcl | 50 | $1,239 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 18 | $628 |
| Ranolazine ErRanolazine | 16 | $612 |
| Metoprolol Tartrate | 42 | $384 |
| Carvedilol | 43 | $384 |
| Atorvastatin Calcium | 28 | $281 |
| Amiodarone Hcl | 14 | $234 |
| Lisinopril | 43 | $206 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Cleveland
- Guilherme AttizzaniCleveland$1.3M
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Mazen HannaCleveland$208K
- Brian HoitCleveland$207K
- Steven NissenCleveland$149K
- Daniel CantillonCleveland$140K
- Serge HarbCleveland$134K
- Wael JaberCleveland$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.